Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

Jean Hoffman-Censits, MD
Published Online: Thursday, Oct 26, 2017



Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Suitable and tolerable treatments such as immunotherapy agents have changed the field of bladder cancer, says Hoffman-Censits, especially for patients who are ineligible for cisplatin.

Looking ahead, Hoffman-Censits says that recent advances with targeted therapy and immunotherapy will hopefully lead to longer survival and higher rates of bladder conservation.
 


Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Suitable and tolerable treatments such as immunotherapy agents have changed the field of bladder cancer, says Hoffman-Censits, especially for patients who are ineligible for cisplatin.

Looking ahead, Hoffman-Censits says that recent advances with targeted therapy and immunotherapy will hopefully lead to longer survival and higher rates of bladder conservation.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x